Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13484325 | 0.88 | ALDH1A1 (0.52) | ALDH1A1CHRM2CA12CA9MEN1 | |
| SCHEMBL2372406 | 0.85 | CHRM2 (0.47) | ALDH1A1CHRM2CA12CA9MEN1 | |
| SCHEMBL5962347 | 0.83 | CHRM2 (0.54) | ALDH1A1CHRM2CA12CA9MEN1 | |
| SCHEMBL9625482 | 0.83 | CHRM2 (0.63) | ALDH1A1CHRM2MEN1CYP1A2CYP2C19 | |
| SCHEMBL11681175 | 0.82 | CHRM2 (0.47) | ALDH1A1CHRM2CA12CA9MEN1 | |
| SCHEMBL7286379 | 0.82 | CHRM2 (0.53) | ALDH1A1CHRM2CA12CA9MEN1 | |
| SCHEMBL3727196 | 0.81 | CHRM2 (0.56) | ALDH1A1CHRM2CA12CA9 | |
| SCHEMBL30214381 | 0.80 | CHRM2 (0.51) | ALDH1A1CHRM2CA12CA9MEN1 | |
| SCHEMBL28964583 | 0.80 | CHRM2 (0.51) | ALDH1A1CHRM2CA12CA9MEN1 | |
| SCHEMBL5681593 | 0.80 | CHRM2 (0.51) | ALDH1A1CHRM2CA12CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703987-B2 | Methods for preparing 2-methoxyisobutylisonitrile and tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate | Draximage Limited (IE) | 2014-04-22 | — | — | US | disclosed |
| US-8703987-B2 | Methods for preparing 2-methoxyisobutylisonitrile and tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate | Draximage Limited (IE) | 2014-04-22 | — | — | US | disclosed |
| US-8703987-B2 | Methods for preparing 2-methoxyisobutylisonitrile and tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate | Draximage Limited (IE) | 2014-04-22 | — | — | US | disclosed |
| US-20100010250-A1 | METHODS FOR PREPARING 2-METHOXYISOBUTYLISONITRILE AND TETRAKIS(2-METHOXYISOBUTYLISONITRILE)COPPER(I) TETRAFLUOROBORATE | Draximage Limited (IE) | 2010-01-14 | — | — | US | disclosed |
| US-20100010250-A1 | METHODS FOR PREPARING 2-METHOXYISOBUTYLISONITRILE AND TETRAKIS(2-METHOXYISOBUTYLISONITRILE)COPPER(I) TETRAFLUOROBORATE | Draximage Limited (IE) | 2010-01-14 | — | — | US | disclosed |
| US-20100010250-A1 | METHODS FOR PREPARING 2-METHOXYISOBUTYLISONITRILE AND TETRAKIS(2-METHOXYISOBUTYLISONITRILE)COPPER(I) TETRAFLUOROBORATE | Draximage Limited (IE) | 2010-01-14 | — | — | US | disclosed |
| EP-2099742-A1 | METHODS FOR PREPARING 2-METHOXYISOBUTYLISONITRILE AND TETRAKIS(2-METHOXYISOBUTYLISONITRILE)COPPER(I) TETRAFLUOROBORATE | Draximage Limited (IE) | 2009-09-16 | — | — | EP | disclosed |
| US-7563920-B2 | Methods for preparing 2-methoxyisobutylisonitrile and tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate | Draximage Limited (IE) | 2009-07-21 | — | — | US | disclosed |
| US-7563920-B2 | Methods for preparing 2-methoxyisobutylisonitrile and tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate | Draximage Limited (IE) | 2009-07-21 | — | — | US | disclosed |
| US-7563920-B2 | Methods for preparing 2-methoxyisobutylisonitrile and tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate | Draximage Limited (IE) | 2009-07-21 | — | — | US | disclosed |
| US-5652247-A | VASOPRESSIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 1997-07-29 | — | — | US | disclosed |
| US-5559230-A | VASOPRESSIN ANTAGONISTS, QUINOLINES, BENZAZEPINES, VASODILATION, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-24 | — | — | US | disclosed |
| EP-0450097-B1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 1996-04-24 | — | — | EP | disclosed |
| US-5498609-A | Benzoazepinyl compounds as oxytocin and vasopressin antagonists | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1996-03-12 | — | — | US | disclosed |
| US-5436254-A | Vaopressin antagonists | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0382185-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1994-06-15 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010250-A1 | METHODS FOR PREPARING 2-METHOXYISOBUTYLISONITRILE AND TETRAKIS(2-METHOXYISOBUTYLISONITRILE)COPPER(I) TETRAFLUOROBORATE | MEN1, CYP2F1, CYP4F11 | ALDH1A1 2915/4885CHRM2 3470/4885CA12 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.